Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors

Trial Profile

Phase IB Study of Pembrolizumab (MK-3475) in Subjects With Select Advanced Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Anal cancer; Carcinoid tumour; Carcinoma; Cervical cancer; Endometrial cancer; Mesothelioma; Neuroendocrine tumours; Oesophageal cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Acronyms KEYNOTE-028
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 08 Nov 2017 Results assessing the safety and efficacy of Pembrolizumab in patients With advanced Esophageal Carcinoma (n=23; Data cutoff: February 20, 2017) published in the Journal of Clinical Oncology
    • 02 Nov 2017 Results (n=24) assessing safety and efficacy of Pembrolizumab in patients with with advanced cervical cancer, published in the Journal of Clinical Oncology.
    • 12 Sep 2017 Results assessing associations between PD-L1 expression and a T-cell inflamed gene expression profile to clinical response in patients with solid tumors from this trial, presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top